$266.00 – $1,712.00
DISEASE INDICATIONS: Risk of cardiovascular events
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Pharmaceuticals and Medical Devices Agency (PMDA)
Verquvo (vericiguat) is a medication used to treat heart failure with reduced ejection fraction (HFrEF) in adult patients. It works by increasing the concentration of cGMP, which relaxes blood vessels and improves blood flow. The FDA approved it in 2021 based on the VICTORIA trial results, which found that it reduced the risk of cardiovascular death and hospitalization for heart failure by 10%.